Beijing Second Pharmaceutical Receives EU cGMP Certification
This article was originally published in PharmAsia News
Executive Summary
Beijing Second Pharmaceutical, Beijing Pharmaceutical Group's pioneer in going overseas, recently received EU cGMP certification after it initiated an international certification application to be a global pharmaceutical competitor. The company-made anti-hypertensive amlodipine tablets will be sold to Europe and the U.S. within the year, marking a breakthrough for the standard of its pharmaceutical formulation. This also represents a milestone for China's pharmaceutical formulation exports. Industry analysts estimate that the country's nearly 6,000 pharmaceutical firms only account for 3 percent of worldwide drug revenues. Oversupply in the domestic market has led to the profit slump, thus going global is a good strategy for local companies. (Click here for more - Chinese Language)
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.